Glaxosmithkline Share News (GSK)

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Vodafone, up 1.8%. The telecommunications firm said it signed a cable wholesale agreement with Telefonica Deutschland to allow the German company to offer broadband services via Vodafone's network. Under the deal, Telefonica DE will be able to market broadband services over the combined Vodafone and Unitymedia cable network in Germany, which covers 23.7 million households, the company explained.----------AstraZeneca, up 1.2%. The Anglo-Swedish drugmaker said trial results of Calquence showed significant increase in time patients lived without progression of chronic lymphocytic leukaemia disease. AstraZeneca said positive results from the Phase III Ascend trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Calquence monotherapy compared to a combination regimen of rituximab plus physician's choice of idelalisib or bendamustine. Importantly, the safety and tolerability of Calquence was consistent with the known profile. Calquence is currently approved for the treatment of adults with relapsed or refractory mantle cell lymphoma in the US, Brazil, the UAE, and Qatar, and is being developed for the treatment of chronic lymphocytic leukaemia and other blood cancers.----------FTSE 250 - WINNERS----------Syncona, up 1.6%. The life-sciences investor said it was encouraged by portfolio firm Blue Earth Diagnostics' prostate cancer imaging tests results. The healthcare company said that a trial on 58 patients of Blue Earth's radiohybrid PSMA-targeted agent, rhPSMA-7, demonstrated sensitivity of 72%, specificity of 93% and diagnostic accuracy 86%, when compared to histopathological findings. Martin Murphy, Chief Executive of Syncona Investment Management Ltd, said: "We are encouraged by these results, which provide further evidence to support the potential clinical utility of rhPSMA-7 in both high-risk primary and recurrent prostate cancer." Syncona owns a 89% stake in Blue Earth Diagnostics. ----------FTSE 250 - LOSERS----------Domino's Pizza, down 5.2%. The pizza delivery chain said it no longer believes its International operations will break even in 2019 after a disappointing first quarter. Domino's International operations - Norway, Sweden, Iceland and Switzerland - saw sales down 2.0% to GBP25.1 million from GBP25.6 million. However, the London-listed firm's domestic unit reported a robust performance in the 13 weeks to March 31, with UK & Ireland system sales up 4.8% to GBP299.3 million from GBP285.5 million. UK like-for-like sales rose 3.1% while in Ireland were up 6.8%. Total group system sales in the period increased 4.3% to GBP324.4 million from GBP311.1 million in the comparative period a year ago. "Domino's is struggling to make their international businesses fire on all cylinders. It is disappointing to see them losing ground in almost all of the areas that the group operates, outside of the UK and Ireland. The trading update is unsurprisingly badly received by the market," said Hargreaves Lansdown's Steve Clayton. ----------G4S, down 3.5%. Canadian firm Garda World Security on Sunday said it does not intend to make an offer for the UK-listed security company. At the beginning of April, Garda World had said it was in the "preliminary stage" of considering an approach to G4S, to be made in cash. At the time, it provided no further details. G4S on Sunday noted the Garda World statement and confirmed that since April it has not received any approach from the Canadian firm. "The group continues to focus on its previously announced review of options for the separation of its Cash Solutions business from the group," G4S said.----------Kier, down 2.5%. The construction firm said Finance Director Bev Dew is to leave the firm by the end of September. Kier did not say why Dew will be departing, but said it has started the search for a successor.----------OTHER MAIN MARKET AND AIM - WINNERS----------Vectura, up 12%. The pharmaceutical company said it won a patent infringement case against blue chip drugmaker GlaxoSmithKline and was awarded USD89.7 million in damages. The decision followed a court process started in 2016, when Vectura filed a patent infringement lawsuit against Glaxo in the US District Court for the District of Delaware related to US sales of three of Glaxo's Ellipta products. Vectura and Glaxo entered into an agreement in 2010 under which Glaxo had taken a license to formulation technology covered by a Vectura patent which expired in 2016. At that time, Glaxo declined to renew the licensing agreement, resulting in the filing of the lawsuit by Vectura. On Friday, a trial by jury found Vectura's claim valid and declared GSK's infringement as "willful". The willfulness finding grants Vectura the right to seek enhanced damages, the company explained. Glaxo however has the option to appeal the decision. Glaxo shares were down 0.4%. ----------OTHER MAIN MARKET AND AIM - LOSERS----------Purplebricks, down 4.6%. The online estate agent said Founder & Chief Executive Michael Bruce is stepping down with immediate effect following a "disappointing" 12 months. Bruce is being replaced as CEO by former Moneysupermarket.com Group Managing Director Vic Darvey. Darvey currently is chief operating officer at Purplebricks, joining only in January. Purplebricks has decided to exit the Australian market. The company said market conditions have become "increasingly challenging", which combined with "execution errors" resulted in the division "not delivering the progress" the company expected. In addition, the company placed its US business under review. Non-Executive Chair Paul Pindar "sincerely apologised" to the company's shareholders for the performance in the past 12 months.----------